Trials / Completed
CompletedNCT01450605
Korean Post-marketing Surveillance for Reyataz®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 601 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Reyataz® so that the regulatory authority can manage the marketing approval properly
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | No Intervention | Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2011-10-12
- Last updated
- 2016-04-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01450605. Inclusion in this directory is not an endorsement.